Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$162.20 USD

162.20
806,247

+0.53 (0.33%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $160.73 -1.47 (-0.91%) 6:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bristol Myers' (BMY) NDA for Mavacamten Accepted by FDA

by Zacks Equity Research

The FDA accepts Bristol Myers' (BMY) new drug application for mavacamten for treating patients with symptomatic obstructive hypertrophic cardiomyopathy.

Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC

by Zacks Equity Research

Exelixis (EXEL) signs a collaboration and supply agreement with Merck KGaA and Pfizer to investigate XL092 in combination with Bavencio for treating various forms of urothelial carcinoma.

Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA

by Zacks Equity Research

The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.

ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA

by Zacks Equity Research

The FDA identifies deficiencies in ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock sinks.

Cara Therapeutics' (CARA) Korsuva NDA Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.

Blueprint Medicines (BPMC) Gets EMA Validation for Ayvakyt in SM

by Zacks Equity Research

The EMA validates Blueprint Medicines' (BPMC) Type II variation marketing authorization application for Ayvakyt to treat advanced systemic mastocytosis.

Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

by Zacks Equity Research

Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.

Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

by Zacks Equity Research

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.

Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit

by Zacks Equity Research

Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion. Stock up.

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.

Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.

Repligen (RGEN) Q4 Earnings & Sales Top, 2021 Outlook Bright

by Zacks Equity Research

Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations. Stock up.

Repligen's (RGEN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Repligen (RGEN) beat estimates for both earnings and revenues in the fourth quarter of 2020.

Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.

Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Repligen (RGEN) closed at $223.39, marking a +1.95% move from the previous day.

Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

Repligen (RGEN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Repligen (RGEN) closed the most recent trading day at $222.06, moving +1.9% from the previous trading session.

Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4%

by Zacks Equity Research

Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod

by Zacks Equity Research

The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.

Mirum Pharmaceuticals (MIRM) in Focus: Stock Moves 5.9% Higher

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Voyager (VYGR) in Focus: Stock Moves 5.7% Higher

by Zacks Equity Research

Voyager (VYGR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.